Crespine Gel is a product based on Last Generation Reticular Hyaluronic Acidof non-animal origin, especially indicated for treat painas well as functional disorders of joints as a result of degenerative deficits. It is also indicated to combat the joint osteoporosis of the knee and hip.
Prior to treatment, a complete anamnesis must be carried out in order to avoid contraindications.
The area should be carefully prepared using an antiseptic. The syringe is removed from the wrapper, the cover is removed from the tip and then the needle is placed carefully.
After its administration, hyaluronic acid forms a layer on the surface of the joint cartilage, which leads to relieve symptoms of pain.
Crespine Gel is marketed in a sterilized wrapper, in a 2-millimeter syringe with Luer lock adapter, which is inside a blister. It consists of a single application.
Also, the use instructions and the labels ? with their corresponding batch number and expiration date ? are presented packaged next to the bluff inside a cardboard box.
Crespine Gel is due injecting intraarticularlyand not in the blood vessels, which could lead to an occlusion of the vessels and, therefore, to suffer an embolism.
The product should not be used if the wrap is open or seems defective. It should also be avoided to mix with other injecting agents.
People who manifest inflammatory infections or processes in the area close to the injection placement point should not be given Crespine Gel.
On the other hand, patients should avoid taking anticoagulants, steroids and high doses of vitamin E before treatmentsince such substances can cause bleeding and inflammation in the area where the injection is placed.
As with injections, in general, patients may have symptoms such as temporary erythema, pain, mild swelling, and feeling warm.
Due to the implantation, in a very low percentage of patients, hypersensitivity to hyaluronic acid can be determined by extensive erythema and swelling.
In any case, we strongly recommend that read the prospect carefully to avoid any unnecessary risk and the procedure is appropriate.
Project co-financed by the European Social Fund Asturias 2014/2020, within the Consolidation operation Ticket Empresarial 2016